Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Mycophenolic Acid 25fludarabine phosphate 21Whole-Body Irradiation 21Cyclophosphamide 21Cyclosporine 16Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Busulfan 14fludarabine 11Cord Blood Stem Cell Transplantation 9Methotrexate 8Melphalan 8Granulocyte Colony-Stimulating Factor 8Cytarabine 8Antilymphocyte Serum 8Filgrastim 7Thiotepa 6Etoposide 6sargramostim 4merphos 4Radiotherapy 4Drug Therapy 4Cyclosporins 4Azacitidine 4thymoglobulin 3Vorinostat 3Sirolimus 3Lenalidomide 3Idarubicin 3tipifarnib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Refractory, with Excess of Blasts × Maraviroc × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡